Noninvasive magnetic resonance (MR) molecular imaging and targeted drug delivery systems, often referred to as theranostic agents, are being developed to enable improved detection, patient risk stratification, site-specific treatment, and longitudinal monitoring. 1 One example of these agents, a gadolinium-based perfluorocarbon nanoparticle, has been used to detect, characterize, treat, and follow angiogenesis in preclinical models of cancer and atherosclerosis.
Noninvasive magnetic resonance (MR) molecular imaging and targeted drug delivery systems, often referred to as theranostic agents, are being developed to enable improved detection, patient risk stratification, site-specific treatment, and longitudinal monitoring. 1 One example of these agents, a gadolinium-based perfluorocarbon nanoparticle, has been used to detect, characterize, treat, and follow angiogenesis in preclinical models of cancer and atherosclerosis. 1l Despite the preclinical success of this and related nanotechnology platforms, the recent discovery of nephrogenic systemic fibrosis (NSF), a serious and unexpected side effect of gadolinium blood pool agents observed in some patients with renal disease or following liver transplant, has cast a shadow on currently approved MR contrast agents.
2 Patients with NSF develop thickening of the skin and connective tissues that can inhibit arm and leg movements and even lead to bone fractures. Approximately 5% of patients experience a rapidly progressive course, which may result in death due to widespread fibrosis. The cause of NSF is unknown and there is no effective treatment of this condition. Although gadolinium has been the dominant paramagnetic metal for MR contrast agents, the issue of NSF has induced consideration of alternative approaches.
Manganese was one of the first reported examples 3,4 of paramagnetic contrast material studied in cardiac and hepatic MRI because of its efficient R 1 enhancement. Similar to Ca 2+ and unlike the lanthanides, manganese is a natural cellular constituent, and often a cofactor for enzymes and receptors. Manganese blood pool agents, such as mangafodipir trisodium, have been approved as a hepatocyte-specific contrast agent with transient side-effects due to dechelation of manganese from the linear chelate. Nontargeted liposomal agents have included MnSO 4 3c or Mn-DTPA. 3d Release of Mn caused by disruption of the vesicles allowed MR detection of sites where the vesicles were non-specifically entrapped.
Manganese(III)-labeled nanobialys (1) are a potential targeted MR theranostic nanoparticle produced by molecular self-assembly of amphiphilic branched polyethylenimine, which has a toroidal shape, tunable particle size, and low polydispersity. The "bialy" shape affords increased stability and presents kinetically stable, porphyrin coupled Mn(III) complexes directly to the surrounding water. In a typical synthesis, commercially available branched polyethylenimines (MW ) 10 kDa) are hydrophobically modified (nominal 55% conjugation of the 1°amine) with linoleic acid by activating the carboxylic acid groups with 1-(3′-dimethylaminopropyl)-3-ethylcarbodiimide methiodide (1.2 equiv) and allowing the reaction overnight at ambient temperature. Supramolecular selfassembly of the amphiphilic polymer in anhydrous chloroform, assumes inverted micellar 5 structures (2) that are able to transfer a water soluble new candidate contrast agent Mn(III)-protoporphyrin chloride (Mn-PPC, 4) into chloroform. Synergistic self-assembly of the agent (3) alone or in presence of biotin-caproyl-DSPE (5 w/w% of total amphiphiles), presumably leads to the bilayer structure of nanobialys (1). The entrapment of manganese within the inverted micelles at the surface of the nanoparticles affords accessibility to water and eliminates detrimental interactions with surface homing ligands or surrounding plasma proteins. Nonbiotinylated (Mn(III)-labeled, 5) and biotinylated nanobialys without metal (6) were produced as controls (Scheme 1).
Hydrodynamic particle size for the biotinylated without metal (180 ( 9 nm), biotinylated-Mn(III)-labeled (190 ( 5 nm) and nonbiotinylated-Mn(III) nanobialys (200 ( 12 nm) were similar with a narrow distribution (polydispersity 0.18 ( 0.01, 0.26 ( 0.01, and 0.17 ( 0.01, respectively). In the anhydrous state, tapping mode atomic force microscopy (AFM) and transmission electron microscopy (TEM) revealed decreased particle height (H av -1 , respectively. The concept of MR molecular imaging of fibrin, a critical component of intravascular thromboses, was studied in vitro. Fibrinrich clots supported on silk suture were suspended in phosphate buffered saline (PBS, pH 7.4) with sealed polystyrene test tubes (75 mm). Nanobialys with biotin and metal (1), with biotin and no metal (6) , or no biotin with metal (5) were targeted to the fibrin clots with classic avidin-biotin interactions and well-characterized biotinylated fibrin-specific monoclonal antibodies (NIB5F3). 7 Magnetic resonance images (3 T) of the clots were acquired using T1-weighted gradient echo images and a birdcage coil oriented with all groups visible within the imaging slice. MR images of clot samples (Figure 2) showed marked contrast enhancement of the fibrin-targeted Mn(III) nanobialys and no contrast improvement from the nontargeted and metal-free nanobialys.
The potential of nanobialys for drug delivery applications was assessed with two candidate chemotherapeutic agents, hydrophilic (e.g., doxorubicin) and hydrophobic (e.g., camptothecin) in vitro (see Supporting Information). Nanobialys were dialyzed in 60000 molecular weight cutoff dialysis tubing against an infinite sink of 0.9% NaCl, 0.2 mg/ml human serum albumin, and 0.05% sodium azide at 37°C, which was sampled and replaced daily. The loading efficiencies of doxorubicin and camptothecin were 98 ( 0.1% and 99 ( 0.1%, respectively, by reverse phase HPLC. Drug release over 3 days was 12 ( 0.6% for doxorubicin and 20 ( 3.5% for camptothecin (Figure 3) .
In summary, nanobialys are a novel theranostic agent, which offers the potential of site-specific MR T1-weighted molecular imaging with manganese (as opposed to gadolinium) as well as local delivery of potent chemotherapy agents. The utility of the MR targeted imaging is supported by its high particulate r1 relaxivity (at 1.5 and 3.0 T) and the strong MR contrast enhancement when targeted to clot. Incorporation of drugs with high efficiency and their retention in dissolution supports the theranostic potential of this platform technology. 
